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Cost-Effectiveness of Aspirin Treatment in the Primary
Prevention of Cardiovascular Disease Events in Subgroups
Based on Age, Gender, and Varying Cardiovascular Risk
Jacoba P. Greving, PhD; Erik Buskens, MD, PhD; Hendrik Koffijberg, PhD; Ale Algra, MD, PhD
Background—Aspirin is effective for the primary prevention of cardiovascular events, but it remains unclear for which
subgroups of individuals aspirin is beneficial. We assessed the cost-effectiveness of aspirin separately for men and
women of different ages with various levels of cardiovascular disease risk.
Methods and Results—A Markov model was developed to predict the number of cardiovascular events prevented,
quality-adjusted life-years, and costs over a 10-year period. Event rates were taken from Dutch population data, and the
relative effectiveness of aspirin was taken from a gender-specific meta-analysis. Sensitivity analyses and Monte Carlo
simulations were conducted to evaluate the robustness of the results. In 55-year-old persons, aspirin prevented
myocardial infarctions in men (127 events per 100 000 person-years) and ischemic strokes in women (17 events per
100 000 person-years). Aspirin implies a net investment and a quality-adjusted life-year gain in men 55 years of age;
the incremental cost-effectiveness ratio was 111 949 euros per quality-adjusted life-year (1 euro$1.27 as of June
2007). Aspirin was cost-effective for 55- and 65-year-old men with moderate cardiovascular risk and men 75 years of
age (10-year cardiovascular disease risk10%). Conversely, aspirin was beneficial for women 65 years of age with high
cardiovascular risk and women 75 years of age with moderate cardiovascular risk (10-year cardiovascular disease risk
15%). Results were sensitive to drug treatment costs, effectiveness of aspirin treatment, and utility of taking aspirin.
Conclusions—Aspirin treatment for primary prevention is cost-effective for men with a 10-year cardiovascular disease risk
of 10% and for women with a risk of 15%. This occurs much later in life for women than men. Therefore,
opportunities for the primary prevention of aspirin seem limited in women, and a differentiated preventive strategy
seems warranted. (Circulation. 2008;117:2875-2883.)
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Aspirin is generally prescribed in the secondary preven-tion of cardiovascular events such as myocardial infarc-
tion, stroke, and cardiovascular death.1 The merits of aspirin
in primary prevention strategies are less clear. Meta-analyses
of randomized primary prevention trials have indicated that
low-dose aspirin (ranging from 100 mg every other day to
500 mg daily) is associated with a reduction in cardiovascular
events.2–5 However, in contrast to this risk reduction, aspirin
increases the risk of hemorrhagic stroke and gastrointestinal
bleeding even at a low dosage.6
Editorial p 2844
Clinical Perspective p 2883
It is difficult to get a clear impression of the risk-to-benefit
ratio of aspirin. Reported relative risks or percentages of
adverse events in the individual trials or meta-analyses are
difficult to trade off directly against cardiovascular events.
The range of severity for each type of event varies consider-
ably, as do long-term consequences. Decision analytic mod-
eling offers an appropriate means to combine all relevant
outcomes into a familiar and standardized measure: quality-
adjusted life-years (QALYs). Previous decision analyses and
economic evaluations have shown that the decision of whether
to take aspirin as the primary prevention for cardiovascular
events depends on the patients’ cardiovascular risk level.7–15
Recently, a meta-analysis of the role of aspirin in the primary
prevention of cardiovascular events revealed important differen-
tial effects of aspirin therapy between men and women.5 Aspirin
reduced the risk of myocardial infarction in men and that of
ischemic stroke in women. None of the previous decision
analyses took these newer, more precise estimates of differential
effects of aspirin therapy between the sexes into account.
The aim of this study was to identify subgroups of
individuals in whom low-dose aspirin in the primary preven-
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tion of cardiovascular disease is beneficial. We developed a
decision model to examine the costs and effects of aspirin
compared with no treatment in men and women of different
ages with various levels of cardiovascular risk.
Methods
Model Structure
We developed a Markov model to compare the possible outcomes of
the 2 strategies: aspirin and no aspirin.16 In this model, cycles of 1
year and a total time horizon of 10 years were used. The model was
designed to simulate cohorts of initially healthy men or women 45,
55, 65, or 75 years of age without a history of cardiovascular disease.
The model consisted of 6 health states: well, post–myocardial
infarction, post–major stroke (ischemic or hemorrhagic), post–minor
stroke (ischemic or hemorrhagic), post–gastrointestinal bleeding,
and death. A graphic presentation of the model is shown in Figure 1.
Each individual in the modeled cohort started in the “well” health
state. From there, age- and gender-specific probabilities of fatal and
nonfatal myocardial infarction, ischemic stroke, hemorrhagic stroke,
gastrointestinal bleeding, or dying of another cause determined who
made transitions to other health states over time. We did not consider
angina pectoris or transient ischemic attacks as separate health states
in our model because insufficient data regarding the effectiveness of
aspirin on these outcomes were available. In addition, these out-
comes are transient health states that may be considered an integral
part of survival with cardiovascular disease, ie, without specific
long-term consequences.
Input Parameters
Input parameters, including transition probabilities, treatment effec-
tiveness of aspirin, and utilities, are shown in Table 1. This table lists
parameters for a 55-year-old person. Table I of the online Data
Supplement lists similar data for persons 45, 65, and 75 years of age.
Because the model cycle is 1 year, transition probabilities are
reflected by annual incidence rates for the events of interest. We
derived incidence estimates of myocardial infarction, ischemic
stroke, and hemorrhagic stroke from a record linkage study of
Figure 1. Decision tree, including Markov process, for the decision of whether to take aspirin for the primary prevention of cardiovas-
cular events in generally healthy persons. Shown is the generic framework of the model. The tree is fully displayed only for the aspirin
treatment arm, but the no aspirin arm has the same detail. The square node at the far left symbolizes the choice between the 2 strate-
gies (aspirin and no aspirin); circles represent chance events. Generally healthy persons cycle through the Markov tree (denoted by a
Markov node) and are at risk annually for myocardial infarction (MI), ischemic stroke, hemorrhagic stroke, gastrointestinal bleeding,
and death.
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routinely collected data on hospital discharges and deaths in the
Netherlands by 10-year age groups and gender.17,18 We calculated
age-specific incidence rates using linear interpolation between age
groups. We used these rates rather than fixed annual rates in our
model because there is an increase in incidence rates with age.
Similarly, we derived age- and gender-specific incidence rates of
gastrointestinal bleeding and case fatality rates of myocardial infarc-
tion, ischemic stroke, and hemorrhagic stroke.18–21 Specific data on
case fatality rates of gastrointestinal bleeding were not available in
the literature. The overall risk of dying as a result of gastrointestinal
bleeding was estimated at 3% and was varied in the sensitivity
analyses. We derived age- and gender-specific annual probabilities
of dying from national life tables.22 These data were used to account
for the fact that the cohort in the model ages.
Population-based studies have provided data on risk of death after
a first nonfatal stroke or myocardial infarction resulting from fatal
recurrent strokes and fatal recurrent cardiac events.23–26 For survi-
vors of a first stroke or myocardial infarction, the long-term risk of
death was approximately twice the risk of dying in the general
population of similar gender and age. Using this 2-fold-increased
risk and mortality data from life tables, we calculated age-adjusted
annual mortality rates for survivors of both nonfatal stroke and
myocardial infarction. We assumed that the risk of permanent severe
disability after stroke is 33%.27
Table 1. Incidence, Case Fatality, and Overall Mortality Rates for a 55-Year-Old Person and Treatment Effectiveness Data of Aspirin,
Utilities, Costs, and Their 95% CIs
Parameters Men Women Distribution Data Source Reference
Incidence rates (per 100 000 person-years)*
Myocardial infarction 426 (413–440) 101 (95–108) Normal Cohort study 17
Ischemic stroke 139 (128–150) 73 (65–82) Normal Cohort study 18
Hemorrhagic stroke 31 (26–36) 19 (15–23) Normal Cohort study 18
Gastrointestinal bleeding 76 (59–93) 32 (21–43) Normal Cohort study 19, 20
1-Year case fatality rate*
Myocardial infarction 0.28 (0.26–0.30) 0.27 (0.23–0.31) Normal Cohort study 21
Ischemic stroke 0.12 (0.09–0.14) 0.11 (0.07–0.14) Normal Cohort study 18
Hemorrhagic stroke 0.44 (0.33–0.56) 0.45 (0.31–0.60) Normal Cohort study 18
Gastrointestinal bleeding 0.03 (0.02–0.04) 0.03 (0.02–0.04) Normal Cohort study 5, 19, 20
Overall 1-year mortality rate
(per 100 000 person-years)*
658 (607–709) 407 (366–448) Normal Actual rates 22
Treatment effectiveness of aspirin
Myocardial infarction 0.68 (0.54–0.86) 1.01 (0.84–1.21) Log linear Meta-analysis 5
Ischemic stroke 1.00 (0.72–1.41) 0.76 (0.63–0.93) Log linear Meta-analysis 5
Hemorrhagic stroke 1.69 (1.04–2.73) 1.07 (0.42–2.69) Log linear Meta-analysis 5
Gastrointestinal bleeding† 1.72 (1.35–2.20) 1.68 (1.13–2.52) Log linear Meta-analysis 5
Utilities‡
Myocardial infarction 0.88 (0.8–0.95) Triangular Interview 7, 11, 28
Major stroke§ 0.5 (0–0.75) Triangular Review 7, 11, 29, 30
Minor stroke§ 0.75 (0.6–0.90) Triangular Review 7, 11, 29, 30
Gastrointestinal bleeding (year 1) 0.94 (0.88–1.0) Triangular Estimate 11
Taking aspirin 0.999 (0.985–1.0) Beta Estimate 7, 11, 29
Annual cost data, euros‡
Aspirin 97    Official tariff 35, 36
Myocardial infarction
During first year 16 570    Cost study 37
During subsequent years 1007    Cost study 38
Major stroke§
During first year 34 585    Cost study 39
During subsequent years 20 194    Cost study 39
Minor stroke§
During first year 6064    Cost study 39
During subsequent years 1038    Cost study 39
Gastrointestinal bleeding (per event) 1625    Estimate 9
Death 2579    Expert opinion 39
*Risk of events and mortality rates increase with advancing age, except for case fatality rates for gastrointestinal bleeding.
†Risk estimates were derived from the effects of aspirin treatment on major bleeding.
‡Utility and cost estimates mentioned for men are identical for women.
§Both ischemic and hemorrhagic stroke.
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The utilities associated with the different health states also were
drawn from the literature and are shown in Table 1.7,11,28–30 In most
cases, they were estimated by time tradeoff techniques described in
the original studies.31 For nonfatal gastrointestinal bleeding that
results in only short-term morbidity, a utility of 0.94 was assigned for
the 1-year period after the event (ie, 3 weeks deducted from overall
survival).11
To undertake comparative analyses of the 2 strategies, we applied
relative effects of aspirin to the risks for the relevant health events,
as indicated by the gender-specific meta-analysis of 6 randomized
controlled trials of aspirin for primary prevention.5 Relative effects
of aspirin were assumed to be constant because systematic reviews
and meta-analyses suggest that relative risk reductions with aspirin
seemed not to vary much across a wide range of underlying risk for
cardiovascular disease and were independent of other preventive
therapies.32,33 In addition, we assumed that treatment effectiveness of
aspirin in terms of relative risks was constant across all ages because
age-specific data were lacking; this assumption is common in
cost-effectiveness models.34
Health Outcomes
We determined the expected number of each of the cardiovascular
disease events (myocardial infarction, ischemic stroke, and hemor-
rhagic stroke) and gastrointestinal bleeding, along with differences in
life-years and QALYs. QALYs were calculated by multiplying the
time a person remained in a certain health state by the utility
associated with that particular health state and subsequent summing
over all health states. Ten-year cardiovascular disease risk was estimated
from the expected number of myocardial infarctions, ischemic strokes,
and hemorrhagic strokes in the no aspirin arm divided by the total
number of simulated persons.
Costs
We conducted our economic analysis from the perspective of the
healthcare payer. The total drug treatment costs were calculated at 97
euros per person per year. Aspirin drug costs were obtained from the
Dutch national drug compendium (19 euros) and increased with the
pharmacists’ fee (26 euros) and prescription costs of the general
practitioner (52 euros) on the assumption that 4 prescriptions were
issued each year.35,36 We distinguished event-related costs and
ongoing costs because healthcare costs immediately after an event
are higher than in the subsequent years after an event. Event-related
costs contained the costs of hospitalization, diagnostic workup,
(surgical) intervention, rehabilitation, and nursing home admission
during the first year after an event. Ongoing costs reflected the costs
of the resource use in the subsequent years after an event. These
costs were assigned to a patient for each year that the patient
remained in a certain health state. Cost estimates of the event-related
costs and ongoing costs were derived from Dutch costs studies, and
if these data were not available, we applied European costs estimates
or estimated them with the help of experts in the field.9,37–39 All cost
estimates are updated to 2005 with the Dutch inflation indexes
(http://statline.cbs.nl) calculated in euros (1 euro$1.27 as of June
2007) and presented in Table 1.
Analysis
Life-years, QALYs, and costs were calculated over the 10-year time
horizon and are presented as the mean outcomes per patient.
Incremental cost-utility ratios were defined as the difference in costs
divided by the difference in QALYs. Treatment was considered
cost-effective at an incremental cost-utility ratio of 20 000 euros per
QALY gained. Sensitivity analyses were performed to evaluate the
effect of varying the input parameters over the ranges given in Table
1. Additionally, we evaluated the following scenarios: (1) Lower
95% CI limits were used as relative risk reduction for cardiovascular
events; (2) no disutility for taking aspirin was examined; (3) drug
treatment costs were limited to costs of aspirin drugs only; and (4)
costs were discounted at 4% and benefits at 1.5% and 4% in
accordance with current guidelines.36 Initially, the model also
contained secondary events. Because modeling secondary events did
not have a large influence on our results, we did not consider events
after the first cardiovascular event in our final model. To assess the
uncertainty around the modeled output, we performed probabilistic
sensitivity analysis using Monte Carlo simulation. We evaluated the
clinical courses of 10 000 hypothetical persons for both strategies
(aspirin versus no aspirin) 2000 times, with each simulation involv-
ing a random draw from each of the input parameter distributions
given in Table 1. Multiple outputs were thus calculated, and 95% CIs
were derived. Acceptability curves were used to express the uncer-
tainty in the incremental cost-utility ratios from the Monte Carlo
simulation. These curves show for each predefined cost-utility ratio
(so-called willingness-to-pay threshold) the probability that the
cost-utility ratio found in the study is acceptable.40 The models were
developed in TreeAge (version TreeAge Pro Suite 2007, TreeAge
Software, Inc, Williamstown, Mass).
The authors had full access to and take responsibility for the integrity
of the data. All authors have read and agree to the manuscript as written.
Results
Health Outcomes
The number and type of events for 10 000 men and women 55
years of age without a history of cardiovascular disease in
both treatment groups estimated by using the Markov model
are presented in Table 2. Aspirin treatment yielded the
greatest reduction in myocardial infarctions in men (127
events per 100 000 person-years) and a small reduction of
ischemic strokes in women (17 events per 100 000 person-
years). For a hypothetical 55-year-old man with no additional
risk factors, aspirin treatment resulted in a slightly increased
life expectancy (from 9.67 to 9.69 years) and increased
QALYs (from 9.63 to 9.64) over 10 years (Table 2). Increas-
ing cardiovascular risk to 5 times the baseline risk resulted in
a considerably higher QALY gain for aspirin treatment
(Table 3). Conversely, for a hypothetical 55-year-old woman
with no additional risk factors, there appears to be no QALY
gain with aspirin treatment. For women, the expected number
of prevented ischemic events was too small to outweigh the
increase in hemorrhagic stroke and gastrointestinal bleeding.
Aspirin treatment resulted in only a very small QALY gain
even when cardiovascular risk was increased 5 times the
baseline risk (Table 4).
Costs and Incremental Cost-Utility Ratios
Substantial differences in costs were observed between men
and women. Median total costs per person for the 10-year
follow-up of a 55-year-old person were about 1350 euros for
men and 600 euros for women. Aspirin treatment was more
expensive, costing 2150 euros for men and 1450 euros for
women (Table 2). For a 55-year-old man with no additional
risk factors, aspirin was more effective and more expensive
than no treatment. The incremental cost-utility ratio of aspirin
treatment compared with no treatment was 111 949 euros per
QALY gained (Table 3). The incremental cost-utility ratio of
aspirin improved as the risk of cardiovascular events in-
creased. For a 55-year-old man with a 2-times-increased
cardiovascular risk, aspirin treatment resulted in an incremen-
tal cost-utility ratio of 20 298 euros per QALY gained
compared with no treatment. With 20 000 euros used as a
threshold for cost-effectiveness, treatment with aspirin was
also cost-effective for men 65 and 75 years of age regardless
of the number of risk factors present (Table 3).
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For most women, aspirin treatment resulted in increased
costs and worse health outcomes. However, women 65 years
of age with a 5-times-increased cardiovascular risk aspirin
tended to have favorable health outcomes against higher costs
compared with no treatment. The incremental cost-utility
ratio of aspirin treatment compared with no treatment was
5747 euros per QALY gained. Treatment with aspirin also
was cost-effective for women 75 years of age with a 2-times-
increased cardiovascular risk but was not cost-effective for
women of the same age without increased cardiovascular risk
Table 2. Simulated Outcomes (Mean of 2000 Simulations) of Effectiveness and Costs of Aspirin Compared With No Aspirin on
Cohorts of 10 000 Dutch Men or Women 55 Years of Age at Baseline Followed Up for 10 Years
Men Women
Aspirin No Aspirin Aspirin No Aspirin
Myocardial infarction, n 275 (243–307) 402 (365–441) 99 (80–119) 98 (78–117)
Ischemic stroke, n 131 (109–154) 131 (109–153) 54 (41–68) 71 (55–88)
Hemorrhagic stroke, n 50 (37–64) 29 (19–41) 20 (12–29) 19 (11–28)
Major gastrointestinal bleeding, n 124 (103–144) 72 (57–89) 52 (39–66) 31 (21–42)
Fatal myocardial infarction, n 88 (64–113) 130 (101–159) 29 (17–43) 29 (18–43)
Fatal ischemic stroke, n 22 (9–39) 22 (9–38) 8 (2–17) 10 (3–20)
Fatal hemorrhagic stroke, n 24 (13–37) 14 (6–26) 9 (4–18) 9 (3–17)
Fatal major gastrointestinal bleeding, n 4 (1–11) 3 (0–7) 2 (0–5) 1 (0–4)
Life expectancy, y 9.687 (9.657–9.715) 9.673 (9.643–9.701) 9.798 (9.775–9.821) 9.798 (9.775–9.820)
QALY expectancy, y 9.641 (9.612–9.668) 9.634 (9.606–9.661) 9.774 (9.751–9.797) 9.781 (9.758–9.804)
Costs per person, euros 2158 (1974–2340) 1358 (1191–1537) 1471 (1362–1594) 581 (457–712)
Numbers are point estimates (95% CIs).
Table 3. Estimated 10-Year Cardiovascular Risk, Life Expectancy, and Costs of Aspirin Compared With No Aspirin on Cohorts of




































2 9.891 9.886 2 (0–4) 9.865 9.869 1 (3–0) 1483 588 896 (798–993) NA
2 Increased
CVD risk
5 9.874 9.862 4 (2–6) 9.835 9.830 2 (0–5) 1884 1074 810 (640–976) 141 160
5 Increased
CVD risk




6 9.687 9.673 5 (2–8) 9.641 9.634 3 (0–5) 2158 1358 801 (649–955) 111 949
2 Increased
CVD risk
11 9.638 9.607 12 (8–15) 9.563 9.532 11 (7–15) 3075 2458 618 (368–858) 20 298
5 Increased
CVD risk




11 9.072 9.041 11 (7–15) 8.998 8.973 9 (5–13) 3272 2549 722 (543–904) 29 483
2 Increased
CVD risk
19 8.944 8.871 26 (21–32) 8.818 8.746 26 (21–32) 4855 4382 473 (165–778) 6570
5 Increased
CVD risk




17 7.617 7.569 18 (12–23) 7.529 7.489 15 (9–20) 4298 3647 651 (489–815) 16 279
2 Increased
CVD risk
30 7.317 7.187 47 (40–55) 7.173 7.046 46 (40–53) 6126 5700 427 (155–684) 3374
5 Increased
CVD risk
56 6.558 6.263 108 (97–118) 6.277 5.980 108 (99–119) 10 465 10 298 167 (291–604) 562
CVD indicates cardiovascular disease; ICER, incremental cost-utility ratio.
*The 10-year cardiovascular disease risk was estimated from the expected number of myocardial infarctions, ischemic strokes, and hemorrhagic strokes in the
no aspirin arm divided by the total number of simulated persons.
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(Table 4). Aspirin treatment was cost-effective for men with
a 10-year cardiovascular disease risk 10% and for women
when the risk was 15%.
Figure 2 presents the acceptability curves for cost-utility
ratios for aspirin treatment compared with no treatment for
55-year-old men with various levels of cardiovascular risk.
The probability that cardiovascular disease prevention with
aspirin therapy is cost-effective increases with an increasing
threshold for the incremental cost-utility; the estimated like-
lihood of a cost-utility ratio falling below the Dutch threshold
of 20 000 euros per QALY gained for a 55-year-old man with
no additional risk factors was 0, but the probability would
increase to 25% if the willingness-to-pay threshold was in-
creased to 80 000 euros per QALY gained, as recently proposed
by the Dutch Council for Public Health and Health Care.41 The
curve for 55-year-old men with a 5-times-increased cardiovas-
Table 4. Estimated 10-Year Cardiovascular Risk, Life Expectancy and Costs of Aspirin Compared With No Aspirin On Cohorts of

































No risk factors 1 9.910 9.910 0 (1–1) 9.892 9.901 3 (4–2) 1241 313 928 (858–989) NA
2 Increased
CVD risk
2 9.903 9.903 0 (1–1) 9.878 9.885 3 (4–1) 1434 546 889 (815–954) NA
5 Increased
CVD risk
4 9.880 9.879 0 (1–2) 9.836 9.838 1 (2–1) 2011 1232 779 (667–872) NA
55-Year-old women
No risk factors 2 9.798 9.798 0 (2–2) 9.774 9.782 3 (4–1) 1471 581 890 (808–968) NA
2 Increased
CVD risk
4 9.782 9.781 0 (1–2) 9.745 9.749 1 (3–0) 1837 1015 822 (730–909) NA
5 Increased
CVD risk
8 9.732 9.728 1 (1–3) 9.660 9.655 2 (0–4) 2909 2281 628 (488–765) 114 356
65-Year-old women
No risk factors 5 9.507 9.505 1 (2–4) 9.467 9.469 1 (3–2) 2118 1340 778 (661–897) NA
2 Increased
CVD risk
9 9.439 9.433 2 (1–5) 9.369 9.362 3 (0–6) 2951 2331 620 (470–758) 85 467
5 Increased
CVD risk
21 9.240 9.225 5 (2–9) 9.095 9.063 12 (8–16) 5284 5099 185 (37–377) 5747
75-Year-old women
No risk factors 12 8.683 8.669 5 (0–10) 8.617 8.601 6 (1–10) 3194 2644 550 (393–701) 34 173
2 Increased
CVD risk
21 8.449 8.418 11 (6–16) 8.340 8.296 16 (11–21) 4645 4396 249 (56–421) 5791
5 Increased
CVD risk
44 7.825 7.759 24 (18–31) 7.594 7.490 38 (32–45) 8383 8849 466 (749–214) 4465
Abbreviations as in Table 3.
*The 10-year cardiovascular disease risk was estimated from the expected number of myocardial infarctions, ischemic strokes, and hemorrhagic strokes in the
no aspirin arm divided by the total number of simulated persons.
Figure 2. Acceptability curves for aspirin
based on multiple simulated incremental
cost-utility ratios for 55-year-old men with
increasing risks for cardiovascular disease.
The x axis shows a range of values that
society may be willing to pay for health
benefits, and the elevation of the curve (on
the y axis) denotes the probability that
aspirin has a incremental cost-utility ratio
that is more favorable than the corre-
sponding willingness to pay. The baseline
risk for 55-year-old men without a history
of cardiovascular disease corresponds to
a 10-year cardiovascular disease risk of
6%, a 2-times-increased cardiovascular
risk to 11%, and a 5-times-increased
vascular risk to 24%.
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cular risk shows a 95% probability that aspirin is cost-effective
at a willingness-to-pay threshold of 6000 euros per QALY
gained. For women with a 5-times-increased cardiovascular risk,
the probability that aspirin had a cost per QALY gained
80 000 euros was estimated at 25%.
Sensitivity Analyses
The results of the cost-utility analysis were sensitive to drug
treatment costs, treatment effectiveness, and utility of taking
aspirin (Table 5). When drug treatment costs were reduced to
costs of aspirin drugs only, the incremental cost-utility ratio
of aspirin treatment compared with no treatment decreased
from 111 949 to 6474 euros per QALY gained for 55-year-
old men with no additional risk factors. When the lower limit
of the 95% CI of the relative risk reduction for cardiovascular
events was used, the QALY gain was doubled compared with
the base case. Assuming no disutility from taking medication
daily also made aspirin twice as (cost-) effective as the base
case. The model results were robust for different discount
scenarios and ranges of other utilities and input parameters as
shown in Table 1.
Discussion
Our analyses indicate that aspirin treatment for the primary
prevention of cardiovascular disease is cost-effective once
cardiovascular risk surpasses a certain threshold. Using the
threshold of 20 000 euros per QALY, aspirin was cost-
effective for men with a 10-year cardiovascular disease risk
10% and for women when the risk was 15%. In general,
this occurs much later in life for women than men. Treatment
with aspirin was cost-effective for men 75 years of age
regardless of the number of risk factors present and for 55-
and 65-year-old men with 2 cardiovascular risk factors (eg,
diabetes mellitus, hypertension, hyperlipidemia, or cigarette
smoking). It also was cost-effective for women 75 years of
age with a 2-times-increased cardiovascular risk and women
65 years of age with 5-times-increased risk.
A gender-specific meta-analysis of 50 000 women and
40 000 men enrolled in 6 randomized controlled trials of
low-dose aspirin in the primary prevention of cardiovascular
events demonstrated that aspirin reduced the risk of overall
cardiovascular events but increased the risk of hemorrhagic
stroke and gastrointestinal bleeding in both sexes.5 It also
reduced the risk of myocardial infarction (but not stroke) in
men and ischemic stroke (but not myocardial infarction) in
women. Despite controversies that exist about the differences
in cardioprotection observed between the sexes,42 we used
those relative risks to identify the specific subgroups for
whom the balance of benefits and harms is most favorable for
aspirin.
In the past decade, several decision analyses and economic
evaluations attempted to balance the benefits and harms of
aspirin therapy.7–15 A decision analysis reported that routine
use of low-dose aspirin is as likely to be associated with benefit
as harm, but that analysis was limited to elderly people without
cardiovascular disease.8 Previous cost-effectiveness analyses
that examined the threshold to recommend aspirin reported
that its use was warranted from a 10-year cardiovascular
disease risk that varied between 7.5% and 15%.9,11,12,14,15 Our
model generally confirmed those results. In contrast to those
earlier studies, we included recent evidence about differential
effects of aspirin therapy between men and women in our
decision model. Furthermore, we distinguished between is-
chemic and hemorrhagic stroke. In addition, we predicted the
benefits in life expectancy, quality-adjusted life expectancy,
and costs of aspirin prevention in a wide range of subgroups,
ie, in men and women of different ages with various levels of
cardiovascular disease. Consequently, our study provides
more complete estimates of the (cost-)effectiveness of the use
of aspirin for the primary prevention of cardiovascular
disease. These analyses provide physicians or decision mak-
ers with quantitative information on the merits of a preventive
strategy. This information may be used to decide whether it
would be cost-effective to prescribe aspirin for a person with
a particular risk profile.
Our model has certain limitations. We did not model patients
with particular cardiovascular risk factors such as diabetes,
hypertension, or smoking because relative risks associated
with aspirin in subgroups of patients with coronary risk
factors were, unfortunately, not available in the literature.
Therefore, the risk of adverse effects such as hemorrhagic
stroke resulting from uncontrolled blood pressure could not
be accounted for. The benefits and cost-effectiveness of
aspirin for patients with high blood pressure may be less
favorable. The simulations were run for 10 years instead of
the complete lifetime. However, 10-year risk estimates are
used commonly in risk prediction charts for cardiovascular
disease prevention.43,44 Moreover, we considered this period
long enough to capture the major health and economic
consequences of taking aspirin in the primary prevention of
cardiovascular events. Our results are based on a model that
did not incorporate the detailed course of persons after their
initial event. Instead, an increased mortality rate was applied
after the onset of a first cardiovascular event, and an average
disability weight was applied to all survivors. This simplified
approach was adopted because modeling secondary events





Base-case analysis* 3 111 949
Relative effectiveness
estimates
Myocardial infarction: 0.54 6 40 375
Ischemic stroke: 0.72 5 44 022
Hemorrhagic stroke: 1.04 5 56 165
Utilities
Taking aspirin: 1 6 47 630
Drug costs




Costs, 4%; benefits, 4% 2 133 853
Costs, 4%; benefits, 1.5% 2 107 098
*Base-case analysis for 55-year-old men with no additional risk factors.
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did not have a large influence on our results, and it prevented
the model from becoming too complex. Another limitation is
that an individual cannot be simulated to experience1 event
in a year because the model operates in discrete 1-year
intervals. However, because secondary cardiovascular events
were not considered, the only shortcoming may be that a
first-ever cardiovascular event cannot occur within the same
cycle as gastrointestinal complications or vice versa. The prob-
ability that those 2 events for an individual occur concomitantly,
however, is very small. Other model limitations were evalu-
ated by changing input parameters in sensitivity analyses.
With regard to drug treatment costs, it appeared that costs of
visiting a physician and pharmacist were important costs to
take into account. The incremental cost-utility ratio of aspirin
treatment compared with no treatment reduced considerably
under an aspirin drug cost-only scenario. Given that aspirin is
easily available over the counter and at a relatively low price,
the possibility of self-medication may be considered. Self-
medication of aspirin would save individuals the time of
consulting a general practitioner and pharmacist and would
reduce the financial burden of drug treatment from the
National Health Service. However, it may not be realistic to
expect that persons are willing to buy aspirin for preventing
a cardiovascular event themselves. The uncertainty of cost
estimates was not considered in our Monte Carlo simulations.
Therefore, the uncertainty in our model outcomes resulted
only from uncertainty in probability parameters, treatment
effectiveness of aspirin, and utilities associated with each
health state. If the uncertainty around cost estimates had been
taken into account, it would have resulted in wider CIs for
costs.
US costs estimates may be different from Dutch cost
estimates. However, a more or less global increase in costs, in
accordance with differences between US and Dutch cost
estimates, is unlikely to change the overall conclusions. In
fact, the incremental cost-effectiveness ratios would probably
be even higher, and these higher ratios would strengthen our
conclusion that aspirin is cost-effective only in persons at
higher cardiovascular risk. Furthermore, Dutch physicians
(and primary care physicians in other Western European
countries) generally know their own patients with vascular
risk factors reasonably well. In primary care settings in the
United States, however, the situation may be different, and
screening costs to identify patients at risk should be taken into
account. Finally, we did not include costs for comedication in
our baseline economic analysis because costs for comedica-
tion will be similar for both strategies (aspirin versus no
aspirin) and therefore the incremental costs will not be
different.
Our results also were sensitive to variations in treatment
efficacy estimates and the utility of taking aspirin, which has
been reported previously.7,11,14 Because a modest disutility of
taking aspirin had important effects on the effectiveness of
aspirin, more research is necessary to determine what
tradeoffs people are willing to make for routine preventive
care. We did not model incomplete adherence for taking
aspirin, although we used efficacy estimates that came from
trials that used intention-to-treat analyses and therefore in-
corporated some of the effects of incomplete adherence.
Recently, it was debated whether physicians have gone too
far with preventive medicine and overresponded to low levels
of risk.45 Primary prevention that is too aggressive might lead
to medicalization of life and turning many healthy people into
worried patients by prescribing drugs for what would previ-
ously have been considered normal and healthy states.
Conclusions
This analysis demonstrated that aspirin treatment for primary
prevention is cost-effective for men with a 10-year cardio-
vascular disease risk10% and for women when the risk was
15%. In general, this occurs much later in life for women
than men. Therefore, opportunities for the primary prevention
of aspirin seem limited in women, and a gender-differentiated
preventive strategy seems warranted.
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CLINICAL PERSPECTIVE
Aspirin is effective for the primary prevention of cardiovascular events, but it remains unclear for which subgroups of
individuals aspirin is beneficial. We assessed the cost-effectiveness of aspirin separately for men and women of different
ages with various levels of cardiovascular disease risk. Our analyses demonstrated that aspirin treatment for the primary
prevention of cardiovascular disease was cost-effective for men with a 10-year cardiovascular disease risk 10% and for
women when the risk was 15%. In general, this occurs much later in life for women than men. Treatment with aspirin
was cost-effective for men 75 years of age regardless of the number of risk factors present and for 55- and 65-year-old men
with 2 cardiovascular risk factors (such as diabetes mellitus, hypertension, hyperlipidemia, or cigarette smoking). For
most women, aspirin treatment resulted in increased costs and worse health outcomes. However, aspirin was cost-effective
for women 65 years of age with high cardiovascular risk and women 75 years of age with moderate cardiovascular risk.
Therefore, opportunities for primary prevention of aspirin seem limited in women, and a gender-differentiated preventive
strategy seems warranted.
Greving et al Cost-Effectiveness of Aspirin Therapy 2883
